LeonaBio, Inc.

LeonaBio, Inc. is a clinical-stage biopharmaceutical company transitioning from its previous identity as Athira Pharma, Inc., with a name change effective January 2026. The company's core focus is developing novel small molecule therapies for conditions with high unmet medical needs, particularly treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). Their lead candidates include lasofoxifene, which is in Phase 3 development for breast cancer through the ELAINE-3 clinical trial, and ATH-1105, currently in Phase 2 development for ALS. The company's strategy centers on advancing these candidates through clinical development with the goal of establishing new standards of care in genetically defined patient populations.

The current registration statement represents a secondary offering rather than a primary capital raise for the company. The 58,464,567 shares being registered are entirely for sale by existing stockholders who participated in the company's December 2025 private placement, where they purchased shares and warrants at $6.35 per share. LeonaBio will not receive any proceeds from the sale of these shares by stockholders. However, the company could receive up to approximately $146.3 million if all warrants are exercised for cash, with proceeds intended for working capital and advancing the drug pipeline. This structure indicates the company recently raised significant capital through the private placement and is now providing liquidity to those investors.

From a governance perspective, the company has substantial insider ownership with directors and executive officers collectively owning 25.12% of outstanding shares. The largest shareholder is Perceptive Entities (controlled by board member Joseph Edelman) with 19.99% ownership. The company has agreed to board representation rights for certain large shareholders, including Commodore Capital and TCG Crossover, and has committed to board changes by mid-2026. As a smaller reporting company and non-accelerated filer, LeonaBio benefits from reduced disclosure requirements but faces the typical challenges of clinical-stage biotech companies, including dependence on successful clinical trial outcomes, regulatory approvals, and future financing needs.

The offering comes at a time when the company's common stock was trading at $8.42 per share as of March 16, 2026, representing a premium to the $6.35 private placement price from December 2025. The registration provides selling stockholders with flexibility to dispose of shares through various methods including ordinary brokerage transactions, block trades, and privately negotiated transactions. For investors, the key considerations will be the clinical progress of lasofoxifene and ATH-1105, the company's cash runway given its clinical-stage status, and the potential dilution from warrant exercises that could significantly increase the share count beyond the current 9.4 million outstanding shares.